SeekingAlpha · Aug 1, 2026
Sumitomo Pharma Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation
2026-08-01. The following slide deck was published by Sumitomo Pharma Co., Ltd.
OTC · SMDPY
Sumitomo Pharma Co., Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$9.09
Up+$0.16 (+1.79%)
Updated Aug 18, 2026, 4:20 PM
SID Score
6.0/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 4.55B
- P/E ratio
- 5.76
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 100
- Avg. volume
- 17
Price performance
SMDPY price history
1M range · 0 trading sessions · Daily adjusted prices
SMDPY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest SMDPY news
The latest Smart Investors Daily articles mentioning SMDPY.
Stock researchCompany · Overview
SMDPY research
Overview
Company profile and research snapshot.
Company profile
SUMITOMO PHARMA CO U/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.40
- Implied upside
- —
- Analysts
- 11
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 9, 2026
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses Strategic Update on Reboot 2027 Progress and Introduction of Boost 2028 Growth Strategy - Slideshow
2026-03-09. The following slide deck was published by Sumitomo Pharma Co., Ltd.
Yahoo · Mar 3, 2026
Middle East War, Oil Outlook Damps Asian Stock Markets
Asian stock markets largely retreated on Tuesday as the war in the Middle East continued, and as oil
Yahoo · Feb 24, 2026
A Look At Sumitomo Pharma’s Valuation As AMCHEPRY Faces Key Japanese Regulatory Milestone
Regulatory milestone draws attention to Sumitomo Pharma stock Sumitomo Pharma (TSE:4506) is in focus after Japan's health authorities scheduled a February 19, 2026 committee meeting to consider manufacturing and marketing authorization for AMCHEPRY, its allogeneic iPS cell based Parkinson's therapy. See our latest analysis for Sumitomo Pharma. The regulatory spotlight on AMCHEPRY arrives after a sharp short term pullback, with a 1 day share price return showing a 9.47% decline and a 7 day...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
